Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

被引：13
|
作者：
Barnet, Megan B. [1 ,2 ,3 ]
Cooper, Wendy A. [3 ,4 ,5 ]
Boyer, Michael J. [3 ,6 ]
Kao, Steven [3 ,6 ]
机构：
[1] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia
[2] Univ New South Wales, Grad Res Sch, Sydney, NSW 2052, Australia
[3] Univ Sydney, Sydney Med Sch, Camperdown, NSW 2006, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW 2006, Australia
[5] Western Sydney Univ, Sch Med, Penrith, NSW 2751, Australia
[6] Chris OBrien Lifehouse, Camperdown, NSW 2006, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 06期
关键词：
non-small cell lung cancer; immunotherapy; checkpoint inhibitors; MAINTENANCE THERAPY; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB; ANTIBODY; NECROSIS; PLACEBO;
D O I：
10.3390/jcm7060151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.
引用
收藏
页数：14
相关论文
共 50 条
  • [21] Biomarkers of immunotherapy in non-small cell lung cancer
    Wang, Lingling
    Hu, Yue
    Wang, Shengchao
    Shen, Jiali
    Wang, Xiaochen
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [22] Vaccines and Immunotherapy for Non-small Cell Lung Cancer
    Morgensztern, Daniel
    Goodgame, Boone
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S463 - S465
  • [23] Updates on immunotherapy in non-small cell lung cancer
    Shimanovsky, Alexei
    Dasanu, Constantin A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (04) : 411 - 418
  • [24] Combination Immunotherapy in Non-small Cell Lung Cancer
    Marmarelis, Melina E.
    Aggarwal, Charu
    CURRENT ONCOLOGY REPORTS, 2018, 20 (07)
  • [25] Perioperative Immunotherapy in Non-Small Cell Lung Cancer
    O'Brien, Jenny
    Bodor, J. Nicholas
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1790 - 1801
  • [26] Immunotherapy for non-small cell lung cancer (NSCLC)
    Frost, Nikolaj
    Reck, Martin
    INNERE MEDIZIN, 2022, 63 (07): : 709 - 716
  • [27] Adjuvant immunotherapy for non-small cell lung cancer
    Tucker, Zachary C. G.
    Laguna, Benjamin A.
    Moon, Edmund
    Singhal, Sunil
    CANCER TREATMENT REVIEWS, 2012, 38 (06) : 650 - 661
  • [28] Changing paradigms of non-small cell lung cancer treatment
    Guerrera, Francesco
    Tabbo, Fabrizio
    Ruffini, Enrico
    Bertoglio, Pietro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4170 - S4172
  • [29] Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer
    Vazquez-Urrutia, Jorge Raul
    Greenberg, Max
    Zhu, Junjia
    Takamori, Shinkichi
    Komiya, Takefumi
    WORLD JOURNAL OF ONCOLOGY, 2024, 15 (05) : 769 - 776
  • [30] Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
    Li, Chenlu
    Pan, Jingjing
    Luo, Jing
    Chen, Xupeng
    BMC PULMONARY MEDICINE, 2021, 21 (01)
12345